IM Cannabis Corp. Common Shares and SELLAS Life Sciences Group, Inc. Common Stock
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands. The company serves medical patients. IM Cannabis Corp. was founded in 2008 and is headquartered in Tel Aviv, Israel.
Open IMCC dashboard ↗SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Open SLS dashboard ↗You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.
Sign in →